Revance Therapeutics, Inc.
Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: Revance Therapeutics, Inc. |
Ticker: | Ticker: RVNC |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC). The investigation concerns whether Revance and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it “received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA.” Due to the dispute with Teoxane, Revance advised that the previously announced tender offer by Crown Laboratories, Inc. had been delayed until at least October 4, 2024. On this news, the price of Revance shares declined by $0.45 per share, or approximately 7.75%, from $5.81 per share on September 22, 2024, to close at $5.37 on September 23, 2024.
On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it “received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA.” Due to the dispute with Teoxane, Revance advised that the previously announced tender offer by Crown Laboratories, Inc. had been delayed until at least October 4, 2024. On this news, the price of Revance shares declined by $0.45 per share, or approximately 7.75%, from $5.81 per share on September 22, 2024, to close at $5.37 on September 23, 2024.